Articles By Jack Cush, MD
Dr. Joseph Flood (1952-2023) - Past ACR President
Dr Joseph Flood, a past president of the American College of Rheumatology, passed away on July 13, 2023 at age 70 due to complications of liver disease, diabetes and liver cancer.
Read Article
MMWR: Arthritis Among Children and Adolescents
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.
Read Article
"Ask Cush Anything" Returns (7.21.2023)
Dr. Jack Cush reviews the news and journal reports and this week, takes on 5 cases/questions from "Ask Cush Anything"
Read Article
Tofactitinib in PsA & RA: Nine Year Safety Data
Tofacitinib is FDA approved for psoriatic arthritis and rheumatoid arthritis, but long term safety outcomes beyond a year are limited. A real-world, post-marketing surveillance of tofacitinib in PsA and RA shows a consistent pattern of safety with no new safety concerns identified.
Read Article
Voclosporin in SLE - Long-Term Safety and Efficacy
The AURORA 2 study evaluated the long-term safety and efficacy of voclosporin lupus nephritis patients and, after three years, demonstrated long term safety and efficacy following the one-year AURORA 1 study.
Read Article
Infectious Risk with B Cell Therapies in Lupus
A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.
Read Article
RNase Treatment of Autoimmune Disorders
U1RNP complex, Ro/SSA and La/SSB are major RNA-containing autoantigens associated with autoimmune disorders. Immune complexes (ICs) composed of RNA-containing autoantigens and autoantibodies are suspected to be involved in the pathogenesis of some systemic autoimmune diseases.
Read Article
Danger with Hydroxychloroquine Nonadherence in SLE
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
Read Article
Hold the Methotrexate for One Week
In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.
Read Article
SLE and Pregnancy Outcomes
Obstetric complications and poor pregnancy outcomes are not uncommon in women with SLE, especially with active disease. A large Spanish cohort trials shows that term pregnancy is more likely before the diagnosis of SLE and that poorer pregnancy outcomes were associated with antibody positivity to anticardiolipin IgG and anti-beta-2- glycoprotein IgG/IgM, but not lupus anticoagulant.
Read Article
